$OMIC
Singular Genomics Systems Inc

2023 Q4 Form 10-Q Financial Statement

#000095017023063724 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $1.081M $462.0K $0.00
YoY Change 41.31%
Cost Of Revenue $1.538M $527.0K $0.00
YoY Change 94.93%
Gross Profit -$457.0K -$65.00K $0.00
YoY Change 1804.17%
Gross Profit Margin -42.28% -14.07%
Selling, General & Admin $13.13M $13.25M $11.96M
YoY Change 11.82% 10.8% 39.89%
% of Gross Profit
Research & Development $11.69M $11.22M $12.73M
YoY Change 8.64% -11.88% 42.9%
% of Gross Profit
Depreciation & Amortization $977.0K $860.0K $639.0K
YoY Change 35.51% 34.59% 110.89%
% of Gross Profit
Operating Expenses $24.82M $24.47M $24.69M
YoY Change 10.3% -0.89% 41.42%
Operating Profit -$25.28M -$24.54M -$24.69M
YoY Change 12.21% -0.63% 41.42%
Interest Expense $2.032M $285.0K $211.0K
YoY Change 42.2% 35.07% -9.83%
% of Operating Profit
Other Income/Expense, Net $2.179M $0.00
YoY Change -100.0%
Pretax Income -$23.25M -$22.36M -$23.79M
YoY Change 10.18% -6.01% 35.09%
Income Tax
% Of Pretax Income
Net Earnings -$23.25M -$22.36M -$23.79M
YoY Change 10.18% -6.01% 35.09%
Net Earnings / Revenue -2150.69% -4839.83%
Basic Earnings Per Share -$0.31 -$0.33
Diluted Earnings Per Share -$0.32 -$0.31 -$0.33
COMMON SHARES
Basic Shares Outstanding 73.38M 73.13M 71.22M
Diluted Shares Outstanding 73.18M 71.22M

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $175.4M $191.1M $264.7M
YoY Change -28.47% -27.8% -25.86%
Cash & Equivalents $16.23M $33.30M $93.26M
Short-Term Investments $159.2M $157.8M $171.4M
Other Short-Term Assets $2.691M $5.900M $4.734M
YoY Change -34.4% 24.63% -34.38%
Inventory $13.57M $13.42M $16.70M
Prepaid Expenses $1.672M $2.991M $3.865M
Receivables $565.0K $400.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $192.2M $210.8M $286.1M
YoY Change -28.39% -26.32% -21.45%
LONG-TERM ASSETS
Property, Plant & Equipment $13.69M $13.43M $9.589M
YoY Change 26.97% 40.01% 95.02%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.150M $112.0K $1.166M
YoY Change -0.17% -90.39% 16.6%
Total Long-Term Assets $73.24M $73.72M $59.36M
YoY Change 23.0% 24.19% 798.86%
TOTAL ASSETS
Total Short-Term Assets $192.2M $210.8M $286.1M
Total Long-Term Assets $73.24M $73.72M $59.36M
Total Assets $265.5M $284.5M $345.5M
YoY Change -19.06% -17.64% -6.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.587M $2.432M $2.975M
YoY Change -16.52% -18.25% 24.48%
Accrued Expenses $6.079M $5.063M $5.480M
YoY Change 32.64% -7.61% 59.16%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.312M
YoY Change
Total Short-Term Liabilities $18.29M $15.45M $14.18M
YoY Change 29.53% 8.99% 136.65%
LONG-TERM LIABILITIES
Long-Term Debt $8.901M $10.18M $10.03M
YoY Change -11.56% 1.49% 1.6%
Other Long-Term Liabilities $650.0K $739.0K $1.023M
YoY Change -35.96% -27.76% -64.77%
Total Long-Term Liabilities $9.551M $10.91M $11.05M
YoY Change -13.8% -1.22% -13.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.29M $15.45M $14.18M
Total Long-Term Liabilities $9.551M $10.91M $11.05M
Total Liabilities $86.46M $85.49M $68.55M
YoY Change 27.8% 24.71% 265.35%
SHAREHOLDERS EQUITY
Retained Earnings -$337.6M -$314.3M -$221.7M
YoY Change 39.04% 41.77% 67.78%
Common Stock $7.000K $7.000K $7.000K
YoY Change 0.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $179.0M $199.0M $276.9M
YoY Change
Total Liabilities & Shareholders Equity $265.5M $284.5M $345.5M
YoY Change -19.06% -17.64% -6.84%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$23.25M -$22.36M -$23.79M
YoY Change 10.18% -6.01% 35.09%
Depreciation, Depletion And Amortization $977.0K $860.0K $639.0K
YoY Change 35.51% 34.59% 110.89%
Cash From Operating Activities -$18.90M -$16.82M -$21.79M
YoY Change -5.1% -22.79% 98.49%
INVESTING ACTIVITIES
Capital Expenditures $392.0K $110.0K -$1.127M
YoY Change -78.44% -109.76% -30.48%
Acquisitions
YoY Change
Other Investing Activities $1.043M -$24.60M -$36.99M
YoY Change -47.56% -33.5% 804.84%
Cash From Investing Activities $651.0K -$24.70M -$38.12M
YoY Change 280.7% -35.2% 567.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 72.00K 0.000 27.00K
YoY Change -90.4% -100.0% -102.05%
NET CHANGE
Cash From Operating Activities -18.90M -16.82M -21.79M
Cash From Investing Activities 651.0K -24.70M -38.12M
Cash From Financing Activities 72.00K 0.000 27.00K
Net Change In Cash -18.18M -41.52M -59.88M
YoY Change -4.3% -30.66% 232.55%
FREE CASH FLOW
Cash From Operating Activities -$18.90M -$16.82M -$21.79M
Capital Expenditures $392.0K $110.0K -$1.127M
Free Cash Flow -$19.29M -$16.93M -$20.66M
YoY Change -11.23% -18.05% 120.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001850906
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration
ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2023#SellingGeneralAndAdministrativeExpense
CY2022Q3 us-gaap Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration
ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2023#SellingGeneralAndAdministrativeExpense
us-gaap Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration
ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2023#SellingGeneralAndAdministrativeExpense
us-gaap Impairment Long Lived Asset Held For Use Statement Of Income Or Comprehensive Income Extensible Enumeration
ImpairmentLongLivedAssetHeldForUseStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
http://fasb.org/us-gaap/2023#SellingGeneralAndAdministrativeExpense
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-2948451
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40443
dei Entity Registrant Name
EntityRegistrantName
Singular Genomics Systems, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Address Address Line1
EntityAddressAddressLine1
3010 Science Park Road
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
333-7830
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
OMIC
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
73384510
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33301000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74266000
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
157416000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
170310000
CY2023Q3 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
399000
CY2022Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
913000
CY2023Q3 us-gaap Inventory Net
InventoryNet
13420000
CY2022Q4 us-gaap Inventory Net
InventoryNet
18221000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6259000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4722000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
210795000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
268432000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
58474000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
45896000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13426000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10784000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1711000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1711000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
112000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1152000
CY2023Q3 us-gaap Assets
Assets
284518000
CY2022Q4 us-gaap Assets
Assets
327975000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2432000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3099000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5063000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4583000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7706000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
6323000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
252000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
113000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
15453000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14118000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
59124000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
42456000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10175000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10065000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
739000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1015000
CY2023Q3 us-gaap Liabilities
Liabilities
85491000
CY2022Q4 us-gaap Liabilities
Liabilities
67654000
CY2023Q3 us-gaap Interest Expense
InterestExpense
285000
CY2022Q3 us-gaap Interest Expense
InterestExpense
211000
us-gaap Interest Expense
InterestExpense
814000
us-gaap Interest Expense
InterestExpense
520000
CY2023Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
2464000
CY2022Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
1115000
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73343510
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
71854688
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
7000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
513580000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
503926000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-214000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-837000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-314346000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-242775000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
199027000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
260321000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
284518000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
327975000
CY2023Q3 us-gaap Revenues
Revenues
462000
CY2022Q3 us-gaap Revenues
Revenues
0
us-gaap Revenues
Revenues
1830000
us-gaap Revenues
Revenues
0
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
527000
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
0
us-gaap Cost Of Revenue
CostOfRevenue
1931000
us-gaap Cost Of Revenue
CostOfRevenue
0
CY2023Q3 us-gaap Gross Profit
GrossProfit
-65000
CY2022Q3 us-gaap Gross Profit
GrossProfit
0
us-gaap Gross Profit
GrossProfit
-101000
us-gaap Gross Profit
GrossProfit
0
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11220000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12732000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36074000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35439000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
13254000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11962000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
41345000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
35518000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
24474000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
24694000
us-gaap Operating Expenses
OperatingExpenses
77419000
us-gaap Operating Expenses
OperatingExpenses
70957000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-24539000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-24694000
us-gaap Operating Income Loss
OperatingIncomeLoss
-77520000
us-gaap Operating Income Loss
OperatingIncomeLoss
-70957000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
63000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-25578000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
218388000
CY2023Q3 omic Vesting Of Common Stock Issued For Early Exercise Of Stock Options
VestingOfCommonStockIssuedForEarlyExerciseOfStockOptions
91000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2794000
us-gaap Interest And Other Income
InterestAndOtherIncome
6763000
us-gaap Interest And Other Income
InterestAndOtherIncome
1699000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2179000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
904000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5949000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1179000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-22360000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-23790000
us-gaap Net Income Loss
NetIncomeLoss
-71571000
us-gaap Net Income Loss
NetIncomeLoss
-69778000
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.99
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.99
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.98
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.98
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
73178822
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
73178822
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
71216292
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71216292
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
72541979
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
72541979
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
71001441
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
71001441
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-22360000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-23790000
us-gaap Net Income Loss
NetIncomeLoss
-71571000
us-gaap Net Income Loss
NetIncomeLoss
-69778000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
114000
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-405000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
623000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1280000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22246000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24195000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-70948000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-71058000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
260321000
CY2023Q1 omic Vesting Of Common Stock Issued For Early Exercise Of Stock Options
VestingOfCommonStockIssuedForEarlyExerciseOfStockOptions
97000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
13000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3081000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
446000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
240325000
CY2023Q2 omic Vesting Of Common Stock Issued For Early Exercise Of Stock Options
VestingOfCommonStockIssuedForEarlyExerciseOfStockOptions
112000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
624000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2842000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
114000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-22360000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
199027000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
336173000
CY2022Q1 omic Vesting Of Common Stock Issued For Early Exercise Of Stock Options
VestingOfCommonStockIssuedForEarlyExerciseOfStockOptions
344000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
34000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3566000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
629000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-22006000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
317482000
CY2022Q2 omic Vesting Of Common Stock Issued For Early Exercise Of Stock Options
VestingOfCommonStockIssuedForEarlyExerciseOfStockOptions
151000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
62000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
489000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3605000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
246000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-23982000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
297561000
CY2022Q3 omic Vesting Of Common Stock Issued For Early Exercise Of Stock Options
VestingOfCommonStockIssuedForEarlyExerciseOfStockOptions
109000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
51000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3399000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
405000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-23790000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
276925000
us-gaap Profit Loss
ProfitLoss
-71571000
us-gaap Profit Loss
ProfitLoss
-69778000
us-gaap Share Based Compensation
ShareBasedCompensation
8717000
us-gaap Share Based Compensation
ShareBasedCompensation
10570000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
3036000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2601000
us-gaap Depreciation
Depreciation
2533000
us-gaap Depreciation
Depreciation
1710000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1900000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Amortization Of Lease Incentives
AmortizationOfLeaseIncentives
1840000
us-gaap Amortization Of Lease Incentives
AmortizationOfLeaseIncentives
0
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
46000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-2031000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
110000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
126000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-514000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
940000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
13793000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-312000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
463000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-1040000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
910000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
0
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
160000
omic Purchases Of Inventory Included In Accrued Expenses
PurchasesOfInventoryIncludedInAccruedExpenses
110000
omic Purchases Of Inventory Included In Accrued Expenses
PurchasesOfInventoryIncludedInAccruedExpenses
0
omic Initial Lease Liability Recognized Upon Lease Commencements
InitialLeaseLiabilityRecognizedUponLeaseCommencements
0
omic Initial Lease Liability Recognized Upon Lease Commencements
InitialLeaseLiabilityRecognizedUponLeaseCommencements
43231000
omic Initial Lease Liability Recognized Upon Adoption Of Asc842
InitialLeaseLiabilityRecognizedUponAdoptionOfAsc842
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1314000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
467000
omic Increase Decrease In Accrued Expenses
IncreaseDecreaseInAccruedExpenses
370000
omic Increase Decrease In Accrued Expenses
IncreaseDecreaseInAccruedExpenses
1202000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
139000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
20000
omic Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-1422000
omic Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-960000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
37000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-54745000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-67177000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
129099000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
139211000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
122846000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
84674000
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
19987000
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
19004000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
578000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4204000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13156000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-39737000
us-gaap Proceeds From Issuance Of Common Stock Dividend Reinvestment Plan
ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan
624000
us-gaap Proceeds From Issuance Of Common Stock Dividend Reinvestment Plan
ProceedsFromIssuanceOfCommonStockDividendReinvestmentPlan
489000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
13000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
147000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
13000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
485000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
624000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
151000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-40965000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-106763000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75977000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
201736000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35012000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
94973000
us-gaap Interest Paid Net
InterestPaidNet
777000
us-gaap Interest Paid Net
InterestPaidNet
374000
omic Lease Liability Recognized Upon Lease Modifications During The Period
LeaseLiabilityRecognizedUponLeaseModificationsDuringThePeriod
19475000
omic Lease Liability Recognized Upon Lease Modifications During The Period
LeaseLiabilityRecognizedUponLeaseModificationsDuringThePeriod
0
omic Inventory Transferred To Property And Equipment
InventoryTransferredToPropertyAndEquipment
6498000
omic Inventory Transferred To Property And Equipment
InventoryTransferredToPropertyAndEquipment
104000
omic Purchases Of Inventory Included In Accounts Payable
PurchasesOfInventoryIncludedInAccountsPayable
647000
omic Purchases Of Inventory Included In Accounts Payable
PurchasesOfInventoryIncludedInAccountsPayable
0
omic Vesting Of Restricted Stock
VestingOfRestrictedStock
300000
omic Vesting Of Restricted Stock
VestingOfRestrictedStock
604000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
0
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
334000
omic Initial Lease Liability Recognized Upon Adoption Of Asc842
InitialLeaseLiabilityRecognizedUponAdoptionOfAsc842
7074000
omic Noncurrent Desposit Transferred To Property And Equipment
NoncurrentDespositTransferredToPropertyAndEquipment
0
omic Noncurrent Desposit Transferred To Property And Equipment
NoncurrentDespositTransferredToPropertyAndEquipment
759000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-314300000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-242800000
CY2023Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
190700000
omic Period Of Operations Sufficient To Fund
PeriodOfOperationsSufficientToFund
P12M
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33301000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74266000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1711000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1711000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35012000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75977000
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
157630000
CY2023Q3 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
-214000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
157416000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
171147000
CY2022Q4 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
-837000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
170310000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
156898000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
155920000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
518000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
14390000
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
157416000
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
170310000
us-gaap Revenue Recognition Allowances
RevenueRecognitionAllowances
<p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:4%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company generates revenue from sales of products, which consist of its G4 instrument, related consumable flow cell kits and services. Revenue from instrument sales is recognized generally upon customer acceptance. Revenue from consumables sales is recognized generally upon shipment to the customer. Revenue from services, which are primarily comprised of assurance or extended warranty–type services, is recognized over the applicable service period.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue is recorded net of discounts and sales taxes. The Company invoices its customers for instruments generally upon acceptance, for consumables generally on delivery, and for services generally in advance of the service period. Invoice terms are generally net 30 days. Cash received from customers in advance of revenue recognition is recorded as a contract liability. The Company’s contracts with its customers generally do not include rights of return or a significant financing component.</span></p><p style="text-indent:4%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company regularly enters into contracts that include a combination of products and services, which are distinct within the context of the contract and are accounted for as separate performance obligations. The transaction price is allocated to each performance obligation in proportion to its standalone selling price. Until the Company has sufficient volume of historical sales data for each performance obligation, the Company determines the standalone selling price using observable prices when available and with consideration of current market conditions, which is primarily based on prices set by management, adjusted for applicable discounts. The Company then recognizes revenue for each performance obligation as that performance obligations is satisfied, as discussed above.</span></p><p style="text-indent:4%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the nine months ended September 30, 2023, the Company recognized </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of revenue for instruments and </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of revenue for consumables and services. Contract liabilities, which consists of deferred revenue, as of September 30, 2023 and December 31, 2022 were </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. As of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023, </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> of this balance was classified as current. Deferred revenue represents the value of performance obligations that have been invoiced but for which revenue has not yet been earned.</span></p><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the nine months ended September 30, 2023, all of the Company’s revenue was generated within the United States. </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During this period, the Company’s top </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customers comprised approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">50</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of its revenue</span>
CY2023Q3 us-gaap Deferred Revenue
DeferredRevenue
200000
CY2022Q4 us-gaap Deferred Revenue
DeferredRevenue
100000
CY2023Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
100000
omic Number Of Customers
NumberOfCustomers
3
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:5pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents and marketable securities. The Company invests its cash equivalents in highly rated money market funds. The Company’s marketable securities consist of short-term investments in a variety of interest-bearing instruments, which have included U.S. government and agency securities, high-grade U.S. corporate bonds and asset-backed securities. Deposits may exceed federally insured limits, and the Company is exposed to credit risk on deposits with financial institutions to the extent account balances exceed the amount insured by the Federal Deposit Insurance Corporation (“FDIC”). The Company is monitoring ongoing events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, including Silicon Valley Bank (“SVB”). On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, which appointed the FDIC as receiver, and all of SVB’s deposits and substantially all of SVB’s assets were transferred into a new entity, Silicon Valley Bridge Bank, N.A. (“SVBB”). On March 12, 2023, the Department of the Treasury, the Federal Reserve and the FDIC jointly released a statement that depositors at SVB would have access to their funds, even those in excess of the standard FDIC insurance limits, under a systemic risk exception. Such parties also announced, among other items, that SVBB had assumed the obligations and commitments of former SVB and that commitments to advance under existing credit agreements with former SVB will be honored by SVBB pursuant to the terms of such credit agreements. On March 27, 2023, First-Citizens Bank &amp; Trust Company (“First Citizens Bank”) assumed all of SVBB’s obligations and commitments, and SVBB began operating as Silicon Valley Bank, a division of First Citizens Bank. Unless otherwise noted herein, all references to SVB or Silicon Valley Bank shall refer to Silicon Valley Bank, a division of First Citizens Bank. In light of the foregoing, the Company does not believe it has exposure to loss as a result of SVB’s receivership. During the periods presented, the Company has not experienced any losses on its cash, restricted cash, cash equivalents or marketable securities.</span></p>
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1900000
CY2023Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4558000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13426000
CY2023Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
10641000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
14508000
CY2023Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
2562000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
3276000
CY2023Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
217000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
437000
CY2023Q3 us-gaap Inventory Net
InventoryNet
13420000
CY2022Q4 us-gaap Inventory Net
InventoryNet
18221000
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2991000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3003000
CY2023Q3 us-gaap Interest Receivable
InterestReceivable
2932000
CY2022Q4 us-gaap Interest Receivable
InterestReceivable
1099000
CY2023Q3 us-gaap Deposits Assets Current
DepositsAssetsCurrent
336000
CY2022Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
620000
CY2023Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
6259000
CY2022Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
4722000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
20473000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
15342000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7047000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10784000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1900000
CY2023Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
4015000
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
3580000
CY2023Q3 omic Accrued Contracted Research Costs Current
AccruedContractedResearchCostsCurrent
234000
CY2022Q4 omic Accrued Contracted Research Costs Current
AccruedContractedResearchCostsCurrent
360000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
413000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
204000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
401000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
439000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5063000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4583000
CY2019Q4 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2023-09-01
us-gaap Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
0.0065
omic Debt Instrument Interest Rate Due On Maturity Date
DebtInstrumentInterestRateDueOnMaturityDate
0.055
CY2021Q3 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
15000000
us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2026-09-01
us-gaap Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
0.0075
omic Debt Instrument Interest Rate Due On Maturity Date
DebtInstrumentInterestRateDueOnMaturityDate
0.04
CY2023Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
300000
CY2022Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
400000
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10500000
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10500000
CY2023Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
325000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
435000
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
10175000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
10065000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
165000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2290000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
5886000
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
4511000
CY2023Q3 omic Long Term Debt Maturities Repayments Of Principal Including Interest Payments
LongTermDebtMaturitiesRepaymentsOfPrincipalIncludingInterestPayments
12852000
CY2023Q3 omic Interest And Final Payment Fee
InterestAndFinalPaymentFee
2352000
CY2023Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
10500000
CY2023Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
325000
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
10175000
CY2023Q3 omic Accrued Payment Related To Milestone
AccruedPaymentRelatedToMilestone
400000
CY2022Q1 us-gaap Payments For Rent
PaymentsForRent
1100000
us-gaap Operating Leases Income Statement Initial Direct Costs
OperatingLeasesIncomeStatementInitialDirectCosts
8800000
us-gaap Variable Lease Cost
VariableLeaseCost
2600000
us-gaap Operating Lease Cost
OperatingLeaseCost
6100000
us-gaap Operating Leases Income Statement Initial Direct Costs
OperatingLeasesIncomeStatementInitialDirectCosts
6400000
CY2022Q3 us-gaap Operating Leases Income Statement Initial Direct Costs
OperatingLeasesIncomeStatementInitialDirectCosts
6400000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
100000
us-gaap Variable Lease Cost
VariableLeaseCost
1800000
us-gaap Operating Lease Cost
OperatingLeaseCost
4500000
CY2023Q3 us-gaap Liabilities Subject To Compromise Capital Lease Obligations And Accrued Interest
LiabilitiesSubjectToCompromiseCapitalLeaseObligationsAndAccruedInterest
19500000
CY2023Q3 omic Lessee Operating Lease Liability Payments Due Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfFiscalYear
1993000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
8094000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5716000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
8607000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
8580000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
8837000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
79058000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
120885000
CY2023Q3 omic Operating Lease Future Minimum Payments Less Discount
OperatingLeaseFutureMinimumPaymentsLessDiscount
-54055000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
66830000
CY2023Q3 omic Less Current Portion
LessCurrentPortion
7706000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
59124000
CY2022Q1 us-gaap Preferred Stock Liquidation Preference
PreferredStockLiquidationPreference
0.0001
CY2022Q1 omic Percentage Of Amended Shares Of Common Stock
PercentageOfAmendedSharesOfCommonStock
0.049
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Description
ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription
The number of shares of common stock reserved for issuance under the 2021 Plan is increased automatically on the first day of each fiscal year, commencing in 2022 and ending in 2031, by a number equal to the lesser of: (i) 5% of the shares of common stock outstanding on the last day of the prior fiscal year; or (ii) the number of shares determined by the Company’s Board of Directors.
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
20571103
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9637022
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.35
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4066881
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.17
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2647750
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.21
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
23479
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.56
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
704611
omic Share Based Compensation Arrangements By Share Based Payment Award Options Forfeited In Period Weighted Average Forfeiture Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageForfeiturePrice
6.35
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11556682
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.35
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y1M6D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
39000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5596954
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.53
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y4M24D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
39000
CY2023Q3 omic Liability For Cash Received From Early Exercise Of Stock
LiabilityForCashReceivedFromEarlyExerciseOfStock
200000
CY2022Q4 omic Liability For Cash Received From Early Exercise Of Stock
LiabilityForCashReceivedFromEarlyExerciseOfStock
500000
CY2023Q3 omic Number Of Early Exercise Stock Option Remain Subject To Repurchase
NumberOfEarlyExerciseStockOptionRemainSubjectToRepurchase
150069
CY2022Q4 omic Number Of Early Exercise Stock Option Remain Subject To Repurchase
NumberOfEarlyExerciseStockOptionRemainSubjectToRepurchase
526660
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2794000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3399000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8717000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10570000
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
22500000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y4M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7355
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.5756
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0405
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0198
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16758264
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12813788

Files In Submission

Name View Source Status
omic-20230930_cal.xml Edgar Link unprocessable
0000950170-23-063724-index-headers.html Edgar Link pending
0000950170-23-063724-index.html Edgar Link pending
0000950170-23-063724.txt Edgar Link pending
0000950170-23-063724-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
omic-20230930.htm Edgar Link pending
omic-20230930.xsd Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
omic-ex10_1.htm Edgar Link pending
omic-ex10_10.htm Edgar Link pending
omic-ex10_2.htm Edgar Link pending
omic-ex10_3.htm Edgar Link pending
omic-ex10_4.htm Edgar Link pending
omic-ex10_5.htm Edgar Link pending
omic-ex10_6.htm Edgar Link pending
omic-ex10_7.htm Edgar Link pending
omic-ex10_8.htm Edgar Link pending
omic-ex10_9.htm Edgar Link pending
omic-ex31_1.htm Edgar Link pending
omic-ex31_2.htm Edgar Link pending
omic-ex32_1.htm Edgar Link pending
omic-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
omic-20230930_def.xml Edgar Link unprocessable
omic-20230930_lab.xml Edgar Link unprocessable
omic-20230930_pre.xml Edgar Link unprocessable
omic-20230930_htm.xml Edgar Link completed
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending